Equity Profile

NUVL

Nuvalent, Inc.

Health CareBiotechnology$8.7B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:30 AM EDT

Nuvalent, Inc. Misses on EPS, Stock Down 1.78%

Metric	Actual	Expected	Surprise
EPS	$-1.39	$-1.31	-2.89%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Nuvalent, Inc. Misses on EPS, Stock Down 1.78%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.39	$-1.31	-2.89%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on the numerical results.

What It Means

Nuvalent, Inc. reported a larger-than-expected loss per share, which contributed to a decline in stock price by 1.78%. The lack of revenue and absence of management commentary suggest uncertainty about the company's current performance and future direction. Investors may be cautious as they await further updates.

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-1.31

Revenue

Although no revenue is expected this quarter, any updates on future revenue generation are crucial for assessing growth potential.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. With a market cap of $8 billion, it operates in the health care sector, aiming to address unmet medical needs through innovative drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q4-2025, Nuvalent reported an EPS of $-1.58, missing estimates by 6.76%. The stock reacted negatively, declining 0.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter for Nuvalent, with a consensus EPS of $-1.31. Given the company's history of missing estimates, investor sentiment may be cautious.

Bull Case

If Nuvalent can show signs of progress in its drug development pipeline or provide positive updates, it could lead to a more optimistic outlook and a potential stock rebound.

Bear Case

Continued losses and lack of revenue could further erode investor confidence, leading to a downward adjustment in stock price.

Key Metrics to Watch

EPS

$-1.31

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue generation are crucial for assessing growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-1.31?

A better-than-expected EPS could signal improvements in operational efficiency or cost management, which would be crucial for investor confidence.

What updates can management provide regarding the drug development pipeline?

Investors will be keen to understand the progress and potential revenue streams from upcoming therapies, which could significantly impact future earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent to achieve better-than-expected results due to recent advancements in its drug pipeline that have not been fully factored into earnings estimates.

Supporting Evidence

The options market is pricing a 5.35% move, indicating significant uncertainty that could lead to a larger reaction than anticipated.

Insider selling activity, while notable, may not reflect the company's long-term potential as the Chief Scientific Officer's sales could be personal financial decisions rather than a lack of confidence in the company's future.

Key Risk

If the company provides positive updates on its drug pipeline, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Nuvalent can demonstrate progress in its financial metrics and drug development, which are critical for its valuation.

Bull Confirmed If

An EPS of $-1.10 or better would confirm a stronger operational performance and potentially improve market sentiment.

Bear Confirmed If

An EPS worse than $-1.60 would reinforce concerns about the company's financial health and lead to increased selling pressure.

Pre-Earnings Positioning

Options Market

Implied Move

±5.35%

Historical Avg

±3.9%

Pricing cheap

The options market is pricing in a significant move post-earnings, indicating uncertainty about the results.

Options are pricing ±2.7% while NUVL has averaged ±3.9% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

33.5%

Calls (400)P/C Ratio: 0.13Puts (500)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$323,164.11

3,093 sh

1 insider

Net

$323,164.11

Net selling

Most Active Insiders· 2 open-market trades

Chief Scientific OfficerPelish Henry E.
$323,164.11

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats EPS expectations, history suggests the stock could rise by around 3.7%, confirming a positive trend in operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline of around 0.84%, reflecting ongoing concerns about profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the drug development pipeline and timelines for upcoming trials.
2Management's commentary on cost management strategies and their impact on EPS.
3Insights into potential partnerships or collaborations that could enhance revenue prospects.
4Details on any regulatory progress or challenges the company is facing.
5Guidance on future revenue expectations or milestones that investors should watch.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

NCLHReported

Norwegian Cruise Line Holdings Ltd.

RecapView

May4

AXSMReported

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-1.31

Revenue

Although no revenue is expected this quarter, any updates on future revenue generation are crucial for assessing growth potential.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q4-2025, Nuvalent reported an EPS of $-1.58, missing estimates by 6.76%. The stock reacted negatively, declining 0.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter for Nuvalent, with a consensus EPS of $-1.31. Given the company's history of missing estimates, investor sentiment may be cautious.

Bull Case

If Nuvalent can show signs of progress in its drug development pipeline or provide positive updates, it could lead to a more optimistic outlook and a potential stock rebound.

Bear Case

Continued losses and lack of revenue could further erode investor confidence, leading to a downward adjustment in stock price.

Key Metrics to Watch

EPS

$-1.31

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue generation are crucial for assessing growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-1.31?

A better-than-expected EPS could signal improvements in operational efficiency or cost management, which would be crucial for investor confidence.

What updates can management provide regarding the drug development pipeline?

Investors will be keen to understand the progress and potential revenue streams from upcoming therapies, which could significantly impact future earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

The options market is pricing a 5.35% move, indicating significant uncertainty that could lead to a larger reaction than anticipated.

Key Risk

If the company provides positive updates on its drug pipeline, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Nuvalent can demonstrate progress in its financial metrics and drug development, which are critical for its valuation.

Bull Confirmed If

An EPS of $-1.10 or better would confirm a stronger operational performance and potentially improve market sentiment.

Bear Confirmed If

An EPS worse than $-1.60 would reinforce concerns about the company's financial health and lead to increased selling pressure.

Pre-Earnings Positioning

Options Market

Implied Move

±5.35%

Historical Avg

±3.9%

Pricing cheap

The options market is pricing in a significant move post-earnings, indicating uncertainty about the results.

Options are pricing ±2.7% while NUVL has averaged ±3.9% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

33.5%

Calls (400)P/C Ratio: 0.13Puts (500)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$323,164.11

3,093 sh

1 insider

Net

$323,164.11

Net selling

Most Active Insiders· 2 open-market trades

Chief Scientific OfficerPelish Henry E.
$323,164.11

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats EPS expectations, history suggests the stock could rise by around 3.7%, confirming a positive trend in operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline of around 0.84%, reflecting ongoing concerns about profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the drug development pipeline and timelines for upcoming trials.
2Management's commentary on cost management strategies and their impact on EPS.
3Insights into potential partnerships or collaborations that could enhance revenue prospects.
4Details on any regulatory progress or challenges the company is facing.
5Guidance on future revenue expectations or milestones that investors should watch.